Petros Pharmaceuticals, Inc. received a delisting notice from Nasdaq for not meeting the minimum stockholders' equity requirement of $2.5 million and held a special meeting on April 10, 2025, where stockholders approved amendments to increase authorized shares and the incentive plan by 1 billion shares.